{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:21:37Z","timestamp":1784211697736,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Departamento Administrativo de Ciencia y Tecnolog\u00eda e Innovaci\u00f3n-Colciencias","award":["1115-569-33419"],"award-info":[{"award-number":["1115-569-33419"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10822-019-00230-y","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T18:39:26Z","timestamp":1571078366000},"page":"845-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations"],"prefix":"10.1007","volume":"33","author":[{"given":"Christian","family":"Bustamante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Asela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4280-5627","authenticated-orcid":false,"given":"Carlos","family":"Muskus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"230_CR1","unstructured":"WHO, \u201cLeishmaniasis Technical Report,\u201d 2010."},{"key":"230_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7:5","journal-title":"PLoS ONE"},{"issue":"3","key":"230_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tmaid.2006.09.004","volume":"5","author":"P Minodier","year":"2007","unstructured":"Minodier P, Parola P (2007) Cutaneous leishmaniasis treatment. Travel Med Infect Dis 5(3):150\u2013158","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"230_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","volume":"5","author":"N Singh","year":"2012","unstructured":"Singh N, Kumar M, Singh RK (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med 5(6):485\u2013497","journal-title":"Asian Pac J Trop Med"},{"issue":"2","key":"230_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/0974-777X.62887","volume":"2","author":"J Chakravarty","year":"2010","unstructured":"Chakravarty J, Sundar S (2010) Drug resistance in leishmaniasis. J Glob Infect Dis 2(2):167\u2013176","journal-title":"J Glob Infect Dis"},{"issue":"2","key":"230_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","volume":"25","author":"CP Adams","year":"2006","unstructured":"Adams CP, Van Brantner V (2006) Market watch : estimating the cost of new drug development\u2014is it really $802 million? Health Aff 25(2):420\u2013428","journal-title":"Health Aff"},{"issue":"8","key":"230_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673\u2013683","journal-title":"Nat Rev Drug Discov"},{"issue":"6\u20138","key":"230_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","volume":"16","author":"S Ekins","year":"2011","unstructured":"Ekins S, Williams, AJ, Krasowski MD, Freundlich JS (2011) In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 16(7\u20138):298\u2013310","journal-title":"Drug Discov Today"},{"issue":"5","key":"230_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","volume":"34","author":"N Novac","year":"2013","unstructured":"Novac N (2013) Challenges and opportunities of drug repositioning. Trends Pharmacol Sci 34(5):267\u2013272","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"230_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1517\/17425250902913808","volume":"5","author":"D Czock","year":"2009","unstructured":"Czock D, Markert C, Hartman B, Keller F (2009) Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol 5(5):475\u2013487","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"21\u201322","key":"230_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.drudis.2013.06.013","volume":"18","author":"BO Villoutreix","year":"2013","unstructured":"Villoutreix BO, Lagorce D, Labb\u00e9 CM, Sperandio O, Miteva MA (2013) One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov Today 18(21\u201322):1081\u20131089","journal-title":"Drug Discov Today"},{"key":"230_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/1471-2105-11-484","volume":"11","author":"AF Fl\u00f3rez","year":"2010","unstructured":"Fl\u00f3rez AF et al (2010) Protein network prediction and topological analysis in Leishmania major as a tool for drug target selection. BMC Bioinform 11:484","journal-title":"BMC Bioinform"},{"key":"230_CR13","unstructured":"Scardoni G and Laudanna C (2012) Network centralities for Cytoscape Centralities. Bioinformatics, pp 1\u20138"},{"issue":"10","key":"230_CR14","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1128\/AAC.00671-11","volume":"55","author":"VM Taylor","year":"2011","unstructured":"Taylor VM et al (2011) In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis. Antimicrob Agents Chemother 55(10):4755\u20134764","journal-title":"Antimicrob Agents Chemother"},{"key":"230_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.actatropica.2011.11.015","volume":"122","author":"SA Pulido","year":"2012","unstructured":"Pulido SA (2012) Acta Tropica Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Acta Trop 122:36\u201345","journal-title":"Acta Trop"},{"key":"230_CR16","first-page":"533","volume":"172","author":"DJ Finney","year":"1952","unstructured":"Finney DJ (1952) Statistical method in biological assay. Stat Method Biol Assay 172:533\u2013534","journal-title":"Stat Method Biol Assay"},{"key":"230_CR17","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"A Schumitzky","year":"2009","unstructured":"Schumitzky A, Wang X, D\u2019Argenio DZ (2009) ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles"},{"issue":"8","key":"230_CR18","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1128\/AAC.00014-08","volume":"52","author":"TPC Dorlo","year":"2008","unstructured":"Dorlo TPC et al (2008) Pharmacokinetics of miltefosine in old world cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52(8):2855\u20132860","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"230_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000048470","volume":"45","author":"MA Amantea","year":"1999","unstructured":"Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD (1999) The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Chemotherapy 45(9):48\u201353","journal-title":"Chemotherapy"},{"issue":"4","key":"230_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1590\/S0074-02761998000400018","volume":"93","author":"B Travi","year":"1998","unstructured":"Travi B, Osorio Y (1998) Failure of albendazole as an alternative treatment of Cutaneous leishmaniasis in the hamster model. Mem Inst Oswaldo Cruz 93(4):515\u2013516","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"2","key":"230_CR21","first-page":"95","volume":"17","author":"I Khan","year":"2007","unstructured":"Khan I, Yasmin R, Sidiqui I (2007) Chloroquine in cutaneous leishmaniasis. J Pakistan Assoc Dermatologists 17(2):95\u2013100","journal-title":"J Pakistan Assoc Dermatologists"},{"issue":"8","key":"230_CR22","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.4049\/jimmunol.136.8.3067","volume":"136","author":"NC Behforouz","year":"1986","unstructured":"Behforouz NC, Wenger CD, Mathison BA (1986) Prophylactic treatment of BALB\/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major. J Immunol 136(8):3067","journal-title":"J Immunol"},{"issue":"1","key":"230_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0166-6851(98)00146-7","volume":"98","author":"KA Werbovetz","year":"1999","unstructured":"Werbovetz KA, Brendle JJ, Sackett DL (1999) Purification, characterization, and drug susceptibility of tubulin from Leishmania. Mol Biochem Parasitol 98(1):53\u201365","journal-title":"Mol Biochem Parasitol"},{"issue":"2","key":"230_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1006\/exmp.2002.2418","volume":"72","author":"AC Cunningham","year":"2002","unstructured":"Cunningham AC (2002) Parasitic adaptive mechanisms in infection by Leishmania. Exp Mol Pathol 72(2):132\u2013141","journal-title":"Exp Mol Pathol"},{"issue":"12","key":"230_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0020-7519(01)00259-4","volume":"31","author":"RJS Burchmore","year":"2001","unstructured":"Burchmore RJS, Barrett MP (2001) Life in vacuoles\u2014nutrient acquisition by Leishmania amastigotes. Int J Parasitol 31(12):1311\u20131320","journal-title":"Int J Parasitol"},{"issue":"1","key":"230_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12639-010-0006-3","volume":"34","author":"B Chawla","year":"2010","unstructured":"Chawla B, Madhubala R (2010) Drug targets in Leishmania. J Parasit Dis 34(1):1\u201313","journal-title":"J Parasit Dis"},{"key":"230_CR27","unstructured":"A. K. Mishra et al. (2017) Discovery of novel inhibitors for Leishmania nucleoside diphosphatase kinase (NDK) based on its structural and functional characterization. J. Comput Aided Mol Des 0(0):0"},{"issue":"8","key":"230_CR28","doi-asserted-by":"publisher","first-page":"e0005876","DOI":"10.1371\/journal.pntd.0005876","volume":"11","author":"LH Patino","year":"2017","unstructured":"Patino LH et al (2017) Spatial distribution, Leishmania species and clinical traits of Cutaneous leishmaniasis cases in the Colombian army. PLoS Negl Trop Dis 11(8):e0005876","journal-title":"PLoS Negl Trop Dis"},{"key":"230_CR29","first-page":"18440","volume":"267","author":"S Mazumder","year":"1992","unstructured":"Mazumder S, Mukherjee T, Ghosh J (1992) Allosteric modulation of Leishmania donovani plasma membrane Ca (2+)-ATPase by endogenous calmodulin. J Biol 267:18440\u201318446","journal-title":"J Biol"},{"issue":"2","key":"230_CR30","first-page":"81","volume":"11","author":"C Folgueira","year":"2008","unstructured":"Folgueira C, Carri\u00f3n J, Moreno J, Saugar JM, Ca\u00f1avate C, Requena JM (2008) Effects of the disruption of the HSP70-II gene on the growth, morphology, and virulence of Leishmania infantum promastigotes. Int Microbiol 11(2):81\u201389","journal-title":"Int Microbiol"},{"issue":"1","key":"230_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1752-0509-6-27","volume":"6","author":"AK Chavali","year":"2012","unstructured":"Chavali AK, Blazier AS, Tlaxca JL, Jensen PA, Pearson RD, Papin JA (2012) Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease. BMC Syst Biol 6(1):27","journal-title":"BMC Syst Biol"},{"key":"230_CR32","first-page":"9","volume":"153","author":"D Rodriguez-contreras","year":"2007","unstructured":"Rodriguez-contreras D, Feng X, Keeney KM, Bouwer HGA, Landfear SM (2007) Phenotypic characterization of a glucose transporter null mutant in Leishmania Mexicana 153:9\u201318","journal-title":"Phenotypic characterization of a glucose transporter null mutant in Leishmania Mexicana"},{"key":"230_CR33","doi-asserted-by":"publisher","first-page":"D932","DOI":"10.1093\/nar\/gkw993","volume":"45","author":"O Ursu","year":"2017","unstructured":"Ursu O et al (2017) DrugCentral: online drug compendium. Nucleic Acids Res 45:D932\u2013D939","journal-title":"Nucleic Acids Res"},{"key":"230_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0091270009343694","volume":"50","author":"Y Jin","year":"2010","unstructured":"Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR (2010) Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 50(1):73\u201380","journal-title":"J Clin Pharmacol"},{"key":"230_CR35","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1128\/AAC.05317-11","volume":"55","author":"G Baheti","year":"2011","unstructured":"Baheti G, Kiser JJ, Havens PL, Fletcher CV (2011) Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother 55(11):5294\u20135299","journal-title":"Antimicrob Agents and Chemother"},{"key":"230_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40262-013-0046-9","volume":"52","author":"JK Duong","year":"2013","unstructured":"Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, Timmins P, Graham GG, Furlong TJ, Greenfield JR, Williams KM, Day RO (2013) Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 52(5):373\u2013384","journal-title":"Clin Pharmacokinet"},{"key":"230_CR37","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1128\/AAC.43.12.3025","volume":"43","author":"KHP Moore","year":"1999","unstructured":"Moore KHP, Yuen GJ, Hussey EK, Pakes GE, Eron JJ, Bartlett JA (1999) Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 43(12):3025\u20133029","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"230_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2210-5-4","volume":"5","author":"Synn\u00f6ve Lindemalm","year":"2005","unstructured":"Lindemalm S, Savic RM, Karlsson MO, Juliusson G, Liliemark J, Albertioni F (2005) Application of population pharmacokinetics to cladribine. BMC Pharmacol 5:4","journal-title":"BMC Pharmacology"},{"issue":"8","key":"230_CR39","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1128\/AAC.42.8.2017","volume":"42","author":"G Gatti","year":"1998","unstructured":"Gatti G, Papa P, Torre D, Andreoni M, Poggio A, Bassetti M, Marone P (1998) Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 42(8):2017\u20132023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-019-00230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-019-00230-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-019-00230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:23:00Z","timestamp":1695316980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-019-00230-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["230"],"URL":"https:\/\/doi.org\/10.1007\/s10822-019-00230-y","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"13 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}